CV signal in osteoporosis trial sinks UCB, Amgen shares
By Mary Romeo | May 22, 2017 | 11:09 PM GMT
Amgen Inc. (NASDAQ:AMGN) and UCB S.A. (Euronext:UCB) no longer expect FDA to approve Evenity romosozumab this year after new data from the Phase III ARCH trial revealed a previously unseen cardiovascular
Read the full 314 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury